Skip to main content

Advertisement

Table 1 Baseline demographics and disease characteristics

From: A randomized, controlled study of peginterferon lambda-1a/ribavirin ± daclatasvir for hepatitis C virus genotype 2 or 3

Parameter 24 weeks lambda/RBV N = 353 12 weeks lambda/RBV + DCV N = 349 24 weeks alfa/RBV N = 172
Age, mean (range), years 48 (20, 72) 47 (18, 74) 46 (21, 73)
Male, n (%) 210 (59) 195 (56) 93 (54)
Race/ethnicity, n (%)
 White 232 (66) 226 (65) 111 (64)
 Black/African American 4 (1) 5 (1) 3 (2)
 Asian 113 (32) 118 (34) 55 (32)
 Other 4 (1) 0 3 (2)
 Hispanic/Latino ethnicity 45 (13) 48 (14) 17 (10)
BL HCV RNA, mean (SD) (log10 IU/mL) 6 (1) 6 (1) 6 (1)
HCV RNA distribution (IU/mL)
 ≥800,000 269 (76) 276 (79) 132 (77)
HCV genotype, n (%)
 Genotype 2 183 (52) 184 (53) 91 (53)
 Genotype 3 170 (48) 165 (47) 81 (47)
Cirrhosis, n (%) 25 (7) 26 (7) 14 (8)
 By biopsy 9 (3) 4 (1) 2 (1)
 By FibroScan 16 (5) 22 (6) 12 (7)
IL28B genotype (RS12979860), n (%)
 CC 180 (51) 192 (55) 94 (55)
 CT 145 (42) 126 (36) 68 (40)
 TT 27 (8) 28 (8) 10 (6)
Body mass index >30 kg/m2, n (%) 54 (15) 62 (18) 21 (12)
  1. alfa peginterferon alfa-2a, BL baseline, DCV daclatasvir, HCV hepatitis C virus, Lambda peginterferon Lambda-1a, RBV ribavirin, SD standard deviation